Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/48918
DC FieldValueLanguage
dc.contributor.authorPérez-Peñate, Gregorio Miguelen_US
dc.contributor.authorJuliá-Serdà, Gabrielen_US
dc.contributor.authorOjeda-Betancort, Nazarioen_US
dc.contributor.authorGarcía-Quintana, Antonioen_US
dc.contributor.authorPulido-Duque, Juanen_US
dc.contributor.authorRodríguez Pérez, Aurelio Eduardoen_US
dc.contributor.authorCabrera-Navarro, Pedroen_US
dc.contributor.authorGómez-Sánchez, Miguel Angelen_US
dc.date.accessioned2018-11-24T02:08:49Z-
dc.date.available2018-11-24T02:08:49Z-
dc.date.issued2008en_US
dc.identifier.issn1053-2498en_US
dc.identifier.urihttp://hdl.handle.net/10553/48918-
dc.description.abstractBackground: Inhaled nitric oxide (iNO) is a potent pulmonary vasodilator, but therapeutic experience in patients with severe pulmonary hypertension is scarce. Methods: Eleven patients with severe pulmonary hypertension, 6 due to pulmonary arterial hypertension and 4 due to chronic thromboembolic disease, were selected for iNO therapy. A phosphodiesterase type 5 inhibitor (PDE5i) was added in cases of clinical worsening. In this study we evaluate the clinical effectiveness and safety of long-term treatment with iNO either alone or combined with a PDE5i. Results: After 1 month of iNO administration, improvements were observed in World Health Organization functional class, Borg scale (p = 0.003), brain natriuretic peptide levels (p = 0.002) and 6-minute walk test (p = 0.003). After 6 months of treatment, 7 patients had clinical deterioration that was reversed upon adding a PDE5i. One of these patients died in Month 8 and another underwent pulmonary transplantation in Month 9. The clinical condition of the remaining 9 patients was unchanged after 1 year. A second right catheterization showed improvement in mean pulmonary arterial pressure (66 +/- 15 mm Hg to 56 +/- 18 mm Hg; p = 0.01), pulmonary vascular resistance (1,234 +/- 380 dyn/s/cm(5) to 911 +/- 410 dyn/s/cm(5); p = 0.008) and cardiac index (2.0 +/- 0.4 liters/min/m(2) to 2.5 +/- 0.4 liters/min/m(2); p = 0.04). There was no significant increase in methemoglobin, no worsening of pulmonary function and no sudden withdrawal syndrome. Conclusions: We suggest that iNO therapy alone or in combination with a PDE5i could be a therapeutic alternative for severe pulmonary hypertension.en_US
dc.languageengen_US
dc.relation.ispartofJournal of Heart and Lung Transplantationen_US
dc.sourceJournal of Heart and Lung Transplantation[ISSN 1053-2498],v. 27(12), p. 1326-1332 (Octubre 2008)en_US
dc.subject32 Ciencias médicasen_US
dc.subject3205 Medicina internaen_US
dc.subject.otherPulmonary hypertensionen_US
dc.subject.otherNitric oxideen_US
dc.subject.otherPhosphodiesterase 5 Inhibitorsen_US
dc.subject.otherCyclic GMPen_US
dc.subject.otherAnticoagulantsen_US
dc.titleLong-term Inhaled Nitric Oxide Plus Phosphodiesterase 5 Inhibitors for Severe Pulmonary Hypertensionen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.healun.2008.08.007en_US
dc.identifier.scopus57049129830-
dc.contributor.authorscopusid6505824399-
dc.contributor.authorscopusid6603171553-
dc.contributor.authorscopusid25522059200-
dc.contributor.authorscopusid55985523200-
dc.contributor.authorscopusid35583852200-
dc.contributor.authorscopusid7006262225-
dc.contributor.authorscopusid6602573187-
dc.contributor.authorscopusid7004142085-
dc.description.lastpage1332en_US
dc.identifier.issue12-
dc.description.firstpage1326en_US
dc.relation.volume27en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.description.numberofpages7en_US
dc.utils.revisionen_US
dc.date.coverdateOctubre 2008en_US
dc.identifier.ulpgcNoen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.jcr3,323-
dc.description.jcrqQ1-
dc.description.scieSCIE-
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0003-0947-263X-
crisitem.author.fullNamePérez Peñate, Gregorio Miguel-
crisitem.author.fullNameRodríguez Pérez, Aurelio Eduardo-
crisitem.author.fullNameCabrera Navarro, Pedro-
Appears in Collections:Artículos
Show simple item record

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.